• CSL entered an exclusive global collaboration with Alentis Therapeutics to co-develop, co-promote lixudebart for rare kidney and liver diseases.
• Deal includes an upfront payment of US$355 million, up to US$1.2 billion in commercial milestones, with global profits split 55% CSL, 45% Alentis.
• CSL will fund the Phase 2 RENAL trial completion, a planned Phase 3 in AAV-RPGN, with additional Phase 2 studies in FSGS, PSC.
• Lixudebart targets claudin-1, positioned as a potential first-in-class therapy with anti-inflammatory, anti-fibrotic effects across organ fibrosis indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief via CNW (Ref. ID: 202610041742CANADANWCANADAPR_C2919) on October 04, 2026, and is solely responsible for the information contained therein.